Skip to main content
Log in

Ulipristal acetate: a guide to its use in emergency contraception

  • Clinical Questions & Answers on Drugs
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Ulipristal acetate, the first of a new class of selective progesterone receptor modulators, is indicated for emergency contraception within 120 hours of unprotected sexual intercourse or contraceptive failure. In clinical trials, a single oral dose of ulipristal acetate was effective in preventing pregnancies in women requesting emergency contraception and provided sustained efficacy throughout the 120-hour postcoital period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Table II
Fig. 1

Similar content being viewed by others

References

  1. McKeage K, Croxtall JD. Ulipristal acetate: a review of its use in emergency contraception. Drugs 2011; 71(7): 935–45

    Article  PubMed  CAS  Google Scholar 

  2. Trussell J, Ellertson C, von Hertzen H, et al. Estimating the effectiveness of emergency contraceptive pills. Contraception 2003; 67(4): 259–65

    Article  PubMed  Google Scholar 

  3. vonHertzen H, Piaggio G, Ding J, et al. Low dose mifeprestone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002 Dec 7; 360(9348): 1803–10

    Article  Google Scholar 

  4. Cheng L, Gülmezoglu AM, Piaggio GGP, et al. Interventions for emergency contraception. Cochrane Database Syst Rev 2008 Apr 16; (2): CD001324

  5. ellaOne (ulipristal acetate 30 mg): summary of product characteristics. London: European Medicines Agency, 2010 Jul 23

  6. ella® (ulipristal acetate) tablet: US prescribing information. Morris-town (NJ): Watson Pharma Inc., 2010 Aug

  7. Brache V, Cochon L, Jesam C, et al. Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Hum Reprod 2010; 25(9): 2256–63

    Article  PubMed  CAS  Google Scholar 

  8. Creinin MD, Schlaff W, Archer DF, et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 2006 Nov; 108(5): 1089–97

    Article  PubMed  CAS  Google Scholar 

  9. Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet 2010 Feb 13; 375(9714): 555–62

    Article  PubMed  CAS  Google Scholar 

  10. Fine P, Mathe H, Ginde S, et al. Ulipristal acetate taken 48–120 hours after intercourse for emergency contraception. Obstet Gynecol 2010 Feb; 115 (2 Pt 1): 257–63

    Article  PubMed  Google Scholar 

  11. Thomas CM, Schmid R, Cameron S. Is it worth paying more for emergency hormonal contraception? The cost-effectiveness of ulipristal acetate versus levonorgestrel 1.5 mg. J Fam Plann Reprod Health Care 2010; 36(4): 197–201

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lesley J. Scott.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scott, L.J., McKeage, K. & Croxtall, J.D. Ulipristal acetate: a guide to its use in emergency contraception. Drugs Ther Perspect 28, 6–9 (2012). https://doi.org/10.2165/11606240-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11606240-000000000-00000

Keywords

Navigation